Soleno Therapeutics (SLNO) Preferred Stock Liabilities (2013 - 2016)
Soleno Therapeutics (SLNO) posted quarterly Preferred Stock Liabilities of $13.0 for Q4 2016, up 160.0% year-over-year from $5.0 in Q1 2016, and up 160.0% quarter-over-quarter from $5.0 in Q4 2015.
Soleno Therapeutics (SLNO) Preferred Stock Liabilities (2013 - 2016) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Preferred Stock Liabilities for 4 consecutive years, with $13.0 the latest figure, recorded in Q4 2016.
- In Q4 2016, Preferred Stock Liabilities rose 160.0% year-over-year to $13.0; the TTM figure through Dec 2016 stood at $13.0 (up 160.0% YoY), while the FY2016 annual figure was $13.0, up 160.0% from the prior year.
- Preferred Stock Liabilities rose to $13.0 in Q4 2016 per SLNO's latest filing, from $5.0 in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $15.4 million in Q3 2014 and bottomed at $5.0 in Q4 2015.
- Historically, Preferred Stock Liabilities has averaged $4.2 million across 4 years, with a median of $750006.5 in 2013.
- On a YoY basis, Preferred Stock Liabilities climbed as much as 160.0% in 2016 and fell as far as 160.0% in 2016.
- Soleno Therapeutics' Preferred Stock Liabilities stood at $1.5 million in 2013, then soared by 929.67% to $15.4 million in 2014, then plunged by 100.0% to $5.0 in 2015, then jumped by 160.0% to $13.0 in 2016.
- Business Quant data shows SLNO's Preferred Stock Liabilities at $13.0 in Q4 2016, $5.0 in Q4 2015, and $15.4 million in Q3 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 13.00 |
| Dec 31, 2015 | 5.00 |
| Sep 30, 2014 | 15.45 Mn |
| Dec 31, 2013 | 1.50 Mn |